title: Adherence to acitretin and home narrowband ultraviolet B phototherapy in patients with psoriasis.
abstract: BACKGROUND
  In the treatment of psoriasis, patient adherence to oral medications is poor and even worse for topical therapy. However, few data exist about adherence rates to home phototherapy, adding to concerns about the appropriateness of home phototherapy as a psoriasis treatment option.
  
  
  OBJECTIVE
  We sought to assess adherence to both oral acitretin and home ultraviolet B phototherapy for the treatment of psoriasis.
  
  
  METHODS
  In all, 27 patients with moderate to severe psoriasis were treated with 10 to 25 mg of acitretin daily, combined with narrowband ultraviolet B, 3 times weekly at home, for 12 weeks. Adherence to acitretin was monitored by an electronic monitoring medication bottle cap, and to phototherapy by a light-sensing data logger.
  
  
  RESULTS
  Adherence data were collected on 22 patients for acitretin and 16 patients for adherence to ultraviolet B. Mean adherence to acitretin decreased steadily during the 12-week trial (slope -0.24), whereas mean adherence to home phototherapy remained steady at 2 to 3 d/wk. Adherence was similar between patients who reported side effects and those who did not.
  
  
  CONCLUSIONS
  Small sample size and lack of follow-up on some patients were limitations of this study.
  
  
  CONCLUSIONS
  Adherence rates to home phototherapy were very good and higher than adherence rates for the oral medication. Side effects of treatment were well tolerated in this small group and did not affect use of the treatment. Home phototherapy with acitretin may be an appropriate option for some patients with extensive psoriasis.
authors.affiliation: Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157-1071, USA.
authors.forename: Brad A
authors.initials: BA
authors.lastname: Yentzer
authors.forename: Christopher B
authors.initials: CB
authors.lastname: Yelverton
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Pearce
authors.forename: Fabian T
authors.initials: FT
authors.lastname: Camacho
authors.forename: Zaineb
authors.initials: Z
authors.lastname: Makhzoumi
authors.forename: Adele
authors.initials: A
authors.lastname: Clark
authors.forename: Ann
authors.initials: A
authors.lastname: Boles
authors.forename: Alan B
authors.initials: AB
authors.lastname: Fleischer
authors.forename: Rajesh
authors.initials: R
authors.lastname: Balkrishnan
authors.forename: Steven R
authors.initials: SR
authors.lastname: Feldman
mesh_terms: D017255:Acitretin / Q000627:therapeutic use*; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance / Q000706:statistics & numerical data*; D011565:Psoriasis / Q000188:drug therapy* / Q000532:radiotherapy*; D014467:Ultraviolet Therapy
chemical_list: D017255:Acitretin